Wockhardt Limited

rs,

OCK/SEC/SE/2022-23/068 21th February, 2023 BSE Limited Corporate Relations Department P J Towers, Dalal Street Mumbai - 400 001 National Stock Exchange of India Limited Listing Department Excha

INR 1,973

ior written approval from Wockhardt Limited. | Page 2 Snapshot of Wockhardt : 9M FY23 Revenues : INR 1,973 Cr. 11 manufacturing facilities across world EBITDA: INR 86 Cr. Long term external D/E Ratio 0.16

INR 86

of Wockhardt : 9M FY23 Revenues : INR 1,973 Cr. 11 manufacturing facilities across world EBITDA: INR 86 Cr. Long term external D/E Ratio 0.16x* 2 R&D centres one each in India, UK, USA ~ 520 scientists

0.16x

973 Cr. 11 manufacturing facilities across world EBITDA: INR 86 Cr. Long term external D/E Ratio 0.16x* 2 R&D centres one each in India, UK, USA ~ 520 scientists with >80 PhD’s, Drug Discovery team >

20%

e each in India, UK, USA ~ 520 scientists with >80 PhD’s, Drug Discovery team > 150 associates1 >20% of the 5,400 global associates based outside India1 International business ~ 75% 3,214 patents fi

75%

50 associates1 >20% of the 5,400 global associates based outside India1 International business ~ 75% 3,214 patents filed; 793 patents granted * Excludes Promoter loans Strictly confidential | Page

32%

ield force ►Amongst TOP 5 Generic Cos ►Largest Generic Cos in hospital products Share Share 32%32% 20%20% 25%25% 6%6% ►Generics ►Hospital segment ►Pediatrics 13%13% | Page 4 Key highlights

25%

ngst TOP 5 Generic Cos ►Largest Generic Cos in hospital products Share Share 32%32% 20%20% 25%25% 6%6% ►Generics ►Hospital segment ►Pediatrics 13%13% | Page 4 Key highlights 11 22 33 44

6%

5 Generic Cos ►Largest Generic Cos in hospital products Share Share 32%32% 20%20% 25%25% 6%6% ►Generics ►Hospital segment ►Pediatrics 13%13% | Page 4 Key highlights 11 22 33 44 Busin

13%

ital products Share Share 32%32% 20%20% 25%25% 6%6% ►Generics ►Hospital segment ►Pediatrics 13%13% | Page 4 Key highlights 11 22 33 44 Business performance Restructuring of US Business A

40%

Grove Few products with high margin manufactured by 3rd party Continue to maintain sales with ~ 40% gross margins US$ 25 Mn fixed cost US$ 25 Mn fixed cost US$ 6 Mn variable cost US$ 6 Mn variable

10 million

vaccine manufacturing at UK Facility • Joint venture of 51:49 in favor of Wockhardt • Received £ 10 million as contribution for reserving capacity- 150 million doses across 15 years • Serum has identified

Key Highlights

3

Key Highlights

• Comprehensive, FDA-approved manufacturing facility for sterile injectables. • Present in key therapies across Cardiac, Pain & Analgesics, Vitamins, Respiratory & Diabetes, Oncology, Anti-Infectives • Collaboration with UK Government and Astrazeneca to manufacture COVID-19 Vaccines. 220 223 208 Accelerated new filings Q3 FY22 Q2 FY23 Q3 FY23 6 9 8 12 12 FY20 FY21 FY22 FY23 FY24e All values in INR Cr. | Page 22 India Business Revenue Performance

Key Highlights

• Therapeutic focus across Diabetes , Nephro, Anti-Infectives, Pain / Analgesics, Vitamins & Nutrients, Neuro / CNS and others. 175 158 150 • One of the few Indian Companies who are into Manufacturing of Insulin, Glargine & OSD in Diabetes Q3 FY22 Q2 FY23 Q3 FY23 • Robust Distribution Network – CNF (20+)/ Stockiest / Distributors (~ 2000) • Only Indian Pharma company to Launch novel NCE in India (Brand name – Emrok & Emrok O) 452 483 • On 9 months basis, Diabetes Biosimilar business grew >20% • Launched Sitagliptin under brand name “Sitawok” 9M FY22 9M FY23 All values in INR Cr. | Page 23 Emerging Markets Business Revenue Performance 9M FY23 Africa Asia CIS LatAm MENA 3% 5% 4% 27% 31% 117 117 New Markets + Others 30% 148

Key Highlights

Q1 FY23 Q2 FY23 Q3 FY23 • De-risked model of Operations - partnerships & relationship building. • Differential & end to end Business model from Research to Manufacturing to Distribution with backward integration of API manufacturing. • Strong Presence in Diabetes Segment – Insulin, Glargine : both Vials & Cartridges • Upcoming Focus – Presence in New Markets / New Segments with high growth potential All values in INR Cr. | Page 24 Growth Drivers | Page 25 Wockhardt 2.0 - Strategic pillars which will drive growth ► Affordable, Complex Generics, Sterile Injectable ► Focus on differentiated products, NDDS, Complex technologies ► Global Gx Market ~ $ 200 Bn Pharma Vaccines (Currently Covid-19) ► Drug Substance and Product Integrated Manufacturing ► 10 Bn doses for EM Biologics ► Focus on Diabetes Biosimilar ► Diabetes injectable Portfolio ► Insulin Glargine, EPO, Patented devices ► Diabetes biologics market ~$ 50 Bn New Drug Discovery ► Focus on global reach Antibiotics drug discovery ► Co